PainReform Provides Regulatory Update on Second Part of its Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery
June 07, 2023 16:30 ET
|
PainReform Ltd
TEL AVIV, Israel, June 07, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of...
PainReform Announces Positive Pharmacokinetic (PK) Data in First Part of Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery
May 18, 2023 09:00 ET
|
PainReform Ltd
TEL AVIV, Israel, May 18, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of...
PainReform Provides Business Update for the First Quarter of 2023
May 15, 2023 16:45 ET
|
PainReform Ltd
TEL AVIV, Israel, May 15, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of...
PainReform CEO to Present at Aegis Virtual Conference on May 4th
May 02, 2023 08:30 ET
|
PainReform Ltd
TEL AVIV, Israel, May 02, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of...
PainReform Announces Positive Safety Data in First Part of Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery
May 01, 2023 08:30 ET
|
PainReform Ltd
TEL AVIV, Israel, May 01, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of...
PainReform CEO to Present at the Sequire Investor Summit in Puerto Rico on April 26th
April 17, 2023 09:00 ET
|
PainReform Ltd
TEL AVIV, Israel, April 17, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of...
PainReform Completes First Part of Phase 3 Clinical Trial in Patients Undergoing Bunionectomy Surgery
March 28, 2023 09:10 ET
|
PainReform Ltd
TEL AVIV, Israel, March 28, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of...
PainReform Provides Year-End Business Update; Commences Phase 3 Clinical Trial of PRF-110 in Bunionectomy
March 16, 2023 08:00 ET
|
PainReform Ltd
TEL AVIV, Israel, March 16, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of...
PainReform Announces Commencement of Phase 3 Clinical Trial to Evaluate PRF-110 in Patients Undergoing Bunionectomy Surgery
March 14, 2023 08:00 ET
|
PainReform Ltd
TEL AVIV, Israel, March 14, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of...
PainReform Ltd. (NASDAQ: PRFX) Announces Receipt of Extension to Meet the Nasdaq’s Minimum Bid Price Requirement
February 07, 2023 16:05 ET
|
PainReform Ltd
TEL AVIV, Israel, Feb. 07, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of...